In pursuit of stability enhancement of a prostate cancer targeting antibody derived from a transgenic animal platform

Venkataramani, S., Ernst, R., Derebe, M.G., et al.

Scientific Reports 2020, vol: 10 doi: 10.1038/s41598-020-66636-z


Accelerated timelines necessitate the discovery of fully human antibodies as biotherapeutics using transgenic animals with a notion that such mAbs bypass humanization. A transgenic animal derived mAb (PCa75) targeted against a prostate cancer antigen had several ‘unusual residues’ (rare somatic hypermutations, rSHM, with positional frequency of <1%) that resulted in compromised biophysical properties (Tm = 61 °C and intrinsic stability ΔGu = 24.3 kJ/mol) and a sub-optimal immunogenicity profile. In our quest for quality medicine, we pursued antibody engineering strategies to enhance the stability of PCa75. PCa62, an engineered variant of PCa75, retained function while significantly improving the drug-like attributes of the molecule (Tm = 75 °C and intrinsic stability ΔGu = 63.5 kJ/mol). rSHM is rather prevalent, 18 out the 21 approved transgenic animal-derived antibodies have at least one ‘unusual residue’. Thus, engineering of rSHM remains critical to enhance the stability and minimize immunogenicity risk of biotherapeutics.

View Publication

Read how Prometheus is impacting Dr. Venkataramani's team's work

Topics: Prometheus – nanoDSF,  Publications




Previous Video
Confirmation of the "Conformation" is key for drug discovery and development
Confirmation of the "Conformation" is key for drug discovery and development

Hear how Dr. Sathya Venkataramani from Janssen Biotherapeutics maximized protein stability using the Promet...

Up next
Stability optimization of engineered mAbs
Stability optimization of engineered mAbs

Want to see more
biologics content?

Explore resources